AZ considers options as US gout drug deal backfires
Ironwood tears up licensing agreement after sales disappoint
X
AZ considers options as US gout drug deal backfires
https://pharmaphorum.com/news/az-considers-options-drug-deal-backfires/
gout
FDA approves Ironwood’s gout combination drug
Good news for Ironwood, which forecast annual sales of up to $300m, despite black box kidney failure warning.
AZ sells US, EU and Latin America rights to gout drug
AZ focused on sales target set by CEO Pascal Soriot.
